← Human Trials & Peer-Reviewed Studies
Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic Patients
Plain-language guide to NCT01599338: not phased interventional trial of Liraglutide, 30 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT01599338
- Phase
- not phased
- Status
- completed
- Start
- 2011-01
- Completion (planned or actual)
- 2011-01
- Participants
- 30 (actual)
- Design
- na, open label (everyone knows who gets what), health_services_research
- Conditions studied
- Type 2 Diabetes Mellitus; Overweight
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
In this not phased trial, researchers set out to test Liraglutide.
However, little is known about their effects on food hedonic sensations and taste perception.
The aim of this study is to investigate the impact of Liraglutide on the liking and wanting components of the food reward system, taste sensitivity and sensory specific satiety in type 2 diabetes mellitus (T2DM) patients.
It had 1 arm (groups): Liraglutide (experimental).
The registry classes the interventions as drug.
Who Took Part
30 actual participants took part.
It was open to people of any sex aged from 18 years up to 80 years.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: With glycemic unbalance despite anti-diabetic treatments and. Overweight (BMI \> 25 kg/m²).
The full record lists 2 inclusion and 12 exclusion criteria; among the exclusions: congestive heart failure,; acute and chronic infection,; evolutive cancer,.
How the Study Was Run
It was run as a single-group and open-label study.
Being open-label, the Liraglutide study did not mask who received what.
Everyone received the same intervention, so there was no separate comparison group inside the trial.
It started in 2011-01 with completion listed for 2011-01.
It ran at 1 site in France.
Its stated primary purpose is health services research.
What Was Measured
Primary outcome: Change in liking and wanting for protein, lipid and glucid foods (time frame: 3 months). Change in sensory specific satiety for protein, lipid and glucid foods (time frame: 3 months). Change in gustative detection thresholds for sweet, bitter and salty tastes (time frame: 3 months).
It also tracked 2 secondary outcomes, for example Change in body mass composition (Dual Energy XRay Absorptiometry) and Change in plasma ghrelin, leptin, and HbA1c levels.
What This Means in Plain Language
Put simply, this is a not phased trial of Liraglutide in 30 people.
Its size is small, so on its own it can only give an early look.
The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Liraglutide compound page, all human trials.
Our Notes on the Compound
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.